LabCorp has expanded access to its at-home collection test kit to individuals nationwide who have symptoms consistent with coronavirus disease 2019 (COVID-19) and those without symptoms who may have been exposed to the virus.
The Pixel by LabCorp COVID-19 Test home collection kit was initially just available to frontline workers and first responders; the FDA granted the test kit Emergency Use Authorization (EUA) in April 2020. The kit allows individuals to collect nasal swab specimens from home and mail the sample to a LabCorp lab for testing. The nasal samples are then analyzed using LabCorp’s COVID-19 RT-PCR Test for the detection of nucleic acid from SARS-CoV-2.
The test can be acquired without any upfront out-of-pocket costs if the individual meets the requirements following completion of an online COVID-19 health screening questionnaire. Test requests are evaluated and authorized by an independent physician if appropriate. The Company states that it has over 200,000 test kits available and is ready to increase capacity as needed.
“Expanding access to our at-home collection test kit is another example of our response to this health crisis and makes it possible for individuals needing testing to perform the collection without having to leave their home,” said president and CEO of LabCorp, Adam Schechter.
For more information visit labcorp.com.
This article originally appeared on MPR